Based outside Ghent, Belgium, Stefaan Van der Meulen heads the Global Clinical Business Development team for NAMSA. Prior to this he was leading the Syntactx offices in Europe as a Managing Partner also overseeing business development for the company on a global scale.Stefaan began his career in the pharmaceutical industry working on early- and late-phase clinical research studies of various sizes and indications. While working at Novartis, he was a global co-driver for their risk-based monitoring initiative, a best practice that is now being applied at Syntactx. At Cordis, a medical device developer and manufacturer, Stefaan concentrated on first-in-human and pivotal studies before transitioning to Core Laboratory and product specialist activities. He also has experience in product life-cycle development from both a clinical and marketing perspective.
Stefaan holds a Master of Biomedical Sciences from Ghent University in Belgium. He is fluent in Dutch, English, and French, and proficient in Italian and German.